Tozorakimab, an investigational monoclonal antibody targeting the IL-33 pathway, significantly reduced moderate-to-severe ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Higher isoflavone consumption is associated with improved respiratory health in former smokers with COPD, highlighting diet's ...
Food choices may quietly shape how well damaged lungs cope with disease. A new study published in Chronic Obstructive ...
AstraZeneca’s pivotal phase III MIRANDA trial of tozorakimab to treat COPD meets primary endpoint: Cambridge, UK Positive high-level res ...
AstraZeneca has reported positive high-level results from the phase 3 MIRANDA trial of tozorakimab, showing a statistically ...
April 2026 Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33-targeting biologic further demonstra ...
April 20 (Reuters) - AstraZeneca said on Monday its experimental treatment tozorakimab showed a "meaningful reduction" in moderate-to-severe flare-ups of chronic obstructive pulmonary disease in a ...
The trio of positive studies means that AZ is in pole position to bring an anti-IL-33 drug to market for COPD, after some ...
Among men without obesity, COPD-SDB overlap vs SDB alone is linked to increased subclinical atherosclerosis and arterial stiffness.
Tozorakimab met its primary endpoint in the MIRANDA trial, demonstrating the potential of IL-33 inhibition to reduce exacerbations and improve outcomes for a broad population of COPD patients. Topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results